Hansoh Pharmaceutical (03692) Announces NMPA Approval for Phase I/II Clinical Trial of HS-10561 Capsule for Chronic Spontaneous Urticaria

Hansoh Pharma (03692) announced that on February 24, 2025, HS-10561 capsules, a Class 1 small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed in collaboration with Guangzhou Lupo Pharmaceuticals Co., Ltd., received clinical trial approval from the National Medical Products Administration (NMPA) of China. The drug is intended to initiate clinical trials for chronic spontaneous urticaria.